Eric A. Klein Archives

Eric A. Klein

Overview of MCED – Performance and Impact on Prostate Cancer

Posted by Eric A. Klein, MD | Nov 2024

Erik A. Klein, MD, highlights data on GRAIL’s multi-cancer early detection (MCED) test, focusing on its performance in identifying prostate cancer. The test detects cancer signals in circulating cell-free DNA from a single blood draw using next-generation sequencing and targeted methylation analysis. This approach aims to complement standard screening methods like PSA tests, addressing the limitations of overdiagnosis associated with PSA alone.

In this 11-minute presentation, Dr. Klein reviews the CCGA and the Pathfinder studies, demonstrating the test’s ability to detect high-grade prostate cancers while minimizing the detection of low-grade or indolent cases. He analyzes data from both studies, indicating that the MCED test detects high-grade and advanced-stage prostate cancers.

Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study

Posted by E. David Crawford, MD | Apr 2020

Daniel W. Lin, MD, and Eric A. Klein, MD, present a point-counterpoint on the conclusions of Dr. Lin’s recently published results of Canary PASS (Prostate Active Surveillance Study), which looked at the ability of the Oncotype DX genomic prostate score (GPS) for predicting adverse pathology (AP) in primarily low-risk prostate cancer patients undergoing active surveillance. Following each presentation, Dr. Lin and Dr. Klein also discuss several follow-up questions related to the study and, more broadly, the future of prostate cancer treatment with E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology.